Logo
Regenovue Sub Q with Lidocaine (1 x 1.1ml)

Regenovue Sub Q with Lidocaine (1 x 1.1ml)

Regenovue

Aesthetic Injectable / Dermal Filler
  • CE Marked hyaluronic acid dermal filler in applicable markets (classification subject to regional medical device regulations).
  • Manufactured under an ISO 13485 Compliant quality management system for medical devices.
  • Utilises highly purified, non Animal HA with low endotoxin and low residual BDDE within internationally accepted safety thresholds.
Cross-linked hyaluronic acid dermal filler for deep wrinkles and volumisation

Description

Regenovue Sub Q with Lidocaine (1 x 1.1ml) is the most viscous, high-density hyaluronic acid dermal filler in the Regenovue range, designed for deep wrinkles, severe folds and structural facial volumisation. Formulated with 24 mg/ml 100% cross-linked, non-animal hyaluronic acid and lidocaine for patient comfort, it provides strong lifting capacity and long-lasting volume. Its thick, monophasic gel is ideal for adding definition to cheeks and cheekbones, enhancing facial contours and improving the appearance of deep lines such as nasolabial folds and marionette lines. The filler is completely biodegradable and fully absorbed by the body over time, with effects typically lasting 8–12 months.

Bnefits

  • Most viscous and dense filler in the Regenovue line, providing strong volumising and lifting capacity for deep tissues.
  • Effectively adds volume to the face and restores or enhances contours (e.g. cheeks and cheekbones) for a healthier, more youthful appearance.
  • Reduces the appearance of deep wrinkles and severe folds, including nasolabial folds and marionette lines.
  • Longer-lasting results, typically 8–12 months depending on area treated, technique and patient factors.
  • Completely dissolvable and fully absorbed by the skin over time, enabling reversibility and natural degradation.
  • Monophasic, 100% cross-linked HA structure offers stable, homogenous gel for smooth and predictable injection.
  • Highly purified hyaluronic acid with low endotoxin and low residual BDDE levels, supporting safety and biocompatibility.
  • Contains lidocaine to reduce pain and improve comfort during injection.
  • Easy to inject and shape for experienced practitioners, allowing precise facial contouring.

Indications

  • Deep to very severe facial wrinkles and folds, including pronounced nasolabial folds and marionette lines.
  • Facial volumisation in areas such as cheeks, cheekbones, chin and jawline.
  • Restoration of age-related volume loss in mid-face and lower face.
  • Structural contouring and lifting for improved definition of cheekbones and facial angles.
  • Correction of deep lines in the mid and lower face where high-viscosity filler support is required.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
  • Lidocaine hydrochloride 3 mg/ml (0.3%) as a local anaesthetic (Sub-Q Plus / Sub Q with Lidocaine variant).
  • Phosphate-buffered saline (PBS) at approximately physiological pH.
  • Very low endotoxin level (typically < 0.0015 IU/mg) and low residual BDDE cross-linker.

Formulation

  • Monophasic, highly cross-linked hyaluronic acid gel with very high viscosity and elasticity.
  • Injectable, sterile, pyrogen-free filler presented in a pre-filled 1.1 ml glass syringe with Luer-lock connection.
  • Designed for injection into the deep dermis or subcutaneous / supraperiosteal planes depending on indication.
  • Non-animal stabilised HA gradually resorbed by the body while maintaining structure during its lifespan.

Packaging

  • Pack contains 1 pre-filled 1.1 ml syringe of Regenovue Sub Q with Lidocaine.
  • Typically supplied with 2 sterile needles (often 27G) for deep dermal / subcutaneous injection (needle specification may vary by distributor).
  • Syringe is seated in a sterile blister tray with tamper-evident sealing inside a printed outer carton.
  • Outer packaging labelled with product name, volume (1.1 ml), HA and lidocaine concentration, batch number, expiry date, manufacturer and regulatory marks.
  • Distributed via professional channels only and labelled for use by trained medical/aesthetic practitioners.

Usage

  • For deep dermal and subcutaneous use only by qualified medical or aesthetic professionals trained in dermal filler techniques.
  • Take a full medical history and assess patient suitability; discuss expectations, risks and alternatives and obtain informed consent.
  • Thoroughly cleanse and disinfect the treatment area; topical anaesthetic may be applied if required, in addition to the lidocaine in the product.
  • Allow the syringe to reach room temperature before use. Using aseptic technique, attach a suitable sterile needle or cannula (e.g. 25–27G) securely to the Luer-lock connection.
  • Inject slowly into the appropriate plane (deep dermis, subcutaneous tissue or supraperiosteal plane) using techniques such as linear threading, depot injections, fanning or cannula-based deposition, depending on area and desired effect.
  • Typically used in cheeks, cheekbones, nasolabial folds, marionette lines, chin or jawline for structural support and volumisation.
  • Avoid overcorrection; build volume gradually and reassess as you proceed.
  • After injection, gently mould and contour to achieve smooth transitions and desired shape without applying excessive force.
  • Advise the patient to avoid strong facial massage, intense exercise, alcohol and exposure to extreme heat (saunas, sunbeds, hot baths) for 24–48 hours post-treatment.
  • Recommend avoiding makeup on treated areas until the following day and using high SPF sun protection routinely.
  • Schedule follow-up to review outcomes and perform touch-up treatments if clinically indicated.
  • Dispose of all used needles and syringes immediately after treatment in appropriate sharps containers; single use only, do not resterilise or reuse.

Contraindications

  • Hypersensitivity or allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics or any component of the product.
  • History of severe allergic reactions or anaphylaxis without specialist assessment.
  • Active skin infection, inflammation, acne flare, herpetic lesions or other dermatologic disease at or near the injection site.
  • Pregnancy and breastfeeding, as elective cosmetic dermal filler procedures are generally not recommended.
  • Autoimmune diseases, uncontrolled systemic illness or significant immunosuppression unless treatment is explicitly approved by a physician.
  • Bleeding disorders, or current use of potent anticoagulants or antiplatelet agents without careful assessment of bleeding risk.
  • Previous permanent or semi-permanent filler in the same area, where interaction may increase adverse event risk.
  • Intravascular injection is strictly contraindicated; avoid injecting into or near major vessels and always aspirate and use safe technique where appropriate.

Adverse Effects

  • Common transient reactions: redness, swelling, tenderness, bruising, itching or pain at injection sites.
  • Temporary nodules, lumps, asymmetry or contour irregularities, which may require massage, monitoring or correction.
  • Less common: prolonged oedema, infection, granuloma formation or local inflammatory responses.
  • Rare but serious complications related to inadvertent intravascular injection, including vascular occlusion, tissue ischaemia/necrosis, and ocular complications such as visual disturbance or blindness; these require immediate emergency management.
  • Potential hypersensitivity or delayed inflammatory reactions, presenting as persistent swelling, induration or erythema; product use should be discontinued and appropriate medical management undertaken.

Storage Conditions

  • Store in original packaging at a controlled temperature, generally between 2°C and 25°C (per manufacturer labelling).
  • Protect from direct sunlight, excessive heat and freezing.
  • Do not use after the expiry date indicated on the packaging.
  • Do not use if the blister, syringe or tamper-evident seal is damaged, or if the gel appears cloudy or contains visible particles.
  • Keep out of reach of children and unauthorised persons.

Duration

Approximate effect duration is 8\u201312 months, varying with treatment area, injection technique, patient age, metabolism and lifestyle.

Onset

Results are usually visible immediately after injection, with final appearance more evident after initial post-injection swelling and redness subside over several days.

Browse more Aesthetic Injectable / Dermal Filler

Top Treatments

Top Cities in the UK